The Indian Council of Medical Research will conduct a survey from next week to examine the effectiveness of AstraZeneca's Covishield and Bharat Biotech's Covaxin in preventing the progression of Covid into a severe form.
In the first of its kind study since the launch of the AstraZeneca s Covishield and Bharat Biotech s Covaxin in the country, the Indian Council of Medical Research (ICMR) will conduct a survey from next week to examine the effectiveness of these vaccines in preventing progression of COVID into a severe form. Around 4,000 people above the age of 45 years who have taken either one or both doses of any of these two vaccines will be reviewed, according to Dr Tarun Bhatnagar, senior scientist at ICMR s National Institute of Epidemiology (NIE) in Chennai. As a part of the study we will take people who are COVID-19 positive and hospitalised and compare their vaccination status with those who have tested COVID negative, Bhatnagar told PTI.
NEW DELHI: In the first of its kind study since the launch of the AstraZeneca s Covishield and Bharat Biotech s Covaxin in the country, the Indian Council of Medical Research (ICMR) will conduct a survey from next week to examine the effectiveness of these vaccines in preventing progression of Covid into a severe form.
Around 4,000 people above the age of 45 years who have taken either one or both doses of any of these two vaccines will be reviewed, according to Dr Tarun Bhatnagar, senior scientist at ICMR s National Institute of Epidemiology (NIE) in Chennai. As a part of the study we will take people who are Covid-19 positive and hospitalised and compare their vaccination status with those who have tested Covid negative, Bhatnagar told PTI.
URL copied
Covaxin has reached 30 cities in the past 30 days
Covaxin, India s indigenous Covid-19 vaccine, has reached 30 cities in the past 30 days, said the vaccine manufacturer Bharat Biotech in a statement on Tuesday. Among 30 cities that have received the Covaxin doses include Delhi, Kolkata, Mumbai, Chennai, Bengaluru, Kochi and Amritsar.
Covaxin is one of the three vaccines that the DGCI has cleared for emergency use in India. The two others are Covishield and Sputnik V. While Covishield is the local version of Oxford-AstraZeneca COVID-19 vaccine and being manufactured by Pune-based Serum Institute of India, Sputnik V is a Russian drug.